m<sup>6</sup>A mRNA Modifications in Glioblastoma: Emerging Prognostic Biomarkers and Therapeutic Targets
Glioblastoma, the most common and aggressive primary brain tumor, is highly invasive and neurologically destructive. The mean survival for glioblastoma patients is approximately 15 months and there is no effective therapy to significantly increase survival times to date. The development of effective...
Main Authors: | Gloria S. Xie, Hope T. Richard |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-02-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/16/4/727 |
Similar Items
-
The Pivotal Role of Chemical Modifications in mRNA Therapeutics
by: Albert Liu, et al.
Published: (2022-07-01) -
Alteration of m<sup>6</sup>A-Tagged RNA Profiles in Bone Originated from Periprosthetic Joint Infection
by: Yuanqing Cai, et al.
Published: (2023-04-01) -
NAT10 as a potential prognostic biomarker and therapeutic target for HNSCC
by: Wenjie Tao, et al.
Published: (2021-08-01) -
Nanoformulations targeting immune cells for cancer therapy: mRNA therapeutics
by: Wei Yang, et al.
Published: (2023-05-01) -
Intracranial delivery of synthetic mRNA to suppress glioblastoma
by: Hao Peng, et al.
Published: (2022-03-01)